Biotech Values

[DewDiligence]

How could they keep a marketed, patented drug from being used in another indication?

Drug/biotech companies almost never sue doctors for off-label use of a competing marketed product that technically infringes on a "use" patent. Hence, the only realistic chance to thwart such use is pushback from third-party payers.

ODE doesn't help with this problem insofar as it merely bars FDA approval of a generic version of the orphan drug.